News in Brief

Published: 1-Mar-2003


  • Bristol-Myers Squibb has agreed to pay US$670m (€626m) to settle numerous lawsuits after it was accused of using illegal tactics to keep lower-priced versions of its medicines, cancer-fighting Taxol and the anti-anxiety drug BuSpar, out of the market for many months. Both drugs are now available as generic medicines.

  • The EU has initiated formal talks ; the first stage of disputes proceedings at the World Trade Organisation ; over import restrictions imposed by the Indian government on a range or products including penicillin, its salts, and derivatives, rifampicin, streptomycins or their derivatives, and first aid boxes or kits.

  • The European Agency for the Evaluation of Medicinal Products (EMEA) has announced that the EU marketing authorisation for hepatitis B treatment Hepacare has been withdrawn by the European Commission. The decision followed manufacturer Celltech Pharmaceuticals' commercial decision to abandon plans to sell the medicine. Alternative vaccines are available in Europe.

  • An EU-funded research project has identified four strains of lactobacilli that could help treat intestinal inflammations and infections. The aim of the Deprohealth scheme, which has received €1.4m ($1.5m) in Brussels money; is to develop oral probiotic bacteria vaccines to counter conditions such as rotavirus, which causes infant diarrhoea, and Crohn's disease. Participating researchers from France, Italy, Belgium, Spain, the UK and Australia have had to identify strains that not only prevented inflammation, but also could withstand human digestive acids.

  • A US federal judge has ruled that an approval letter with a delayed effective date given by the FDA should be considered merely a tentative approval and does not give a manufacturer the legal right to begin marketing a medicine. The judge was ruling against Barr Laboratories' bid to market a generic version of tamoxifen tablets, which the company had expected to release last August. He quashed a bid by Barr to overturn FDA restrictions on selling a product ahead of its release. The FDA had stressed that Barr should wait until the original patent currently held by AstraZeneca had expired.
    See more

    • You may also like

    You need to be a subscriber to read this article.
    Click here to find out more.
    Manufacturing

    Accelerating the development of bispecific antibodies

    Read more
    Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market

    Trending Articles

    1. Adragos Pharma acquires Sanofi's Maisons-Alfort sterile fill-finish facility to strengthen European injectables network Global CDMO Adragos Pharma has completed the acquisition of one of Europe's largest sterile injectables manufacturing sites from Sanofi in Maisons-Alfort, France, adding high-volume pre-filled syringe capabilities to its existing fill-finish operations in Switzerland and Livron
    2. Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
    3. FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
    4. Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
    5. Marchesini Group at Interpack 2026 Sustainability, primary packaging, aseptic production, robotics and digital innovation at the heart of this edition

    Upcoming event

    Making Pharmaceuticals

    21–22 April 2026 | Exhibition | Coventry, UK     See all

    You may also like

    You need to be a subscriber to read this article.
    Click here to find out more.
    Manufacturing

    Accelerating the development of bispecific antibodies

    Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market
    Analysis

    Conjugation chemistry key to unlocking next-generation oligonucleotide therapies, says Bachem

    As demand for oligonucleotide therapeutics accelerates, Bachem's Director of Oligonucleotide Production explains how conjugation chemistry is helping CDMOs overcome delivery challenges
    Manufacturing

    UK pharmaceutical manufacturers struggling to meet F-Gas compliance amid ageing cooling infrastructure

    A new Aggreko report reveals that nearly all UK pharmaceutical manufacturers are facing barriers to upgrading cooling systems ahead of the accelerating F-Gas phase-down timeline
    Regulatory

    UK REACH ATRm: CBA welcomes progress but warns of significant hurdles ahead

    The Chemical Business Association has acknowledged long-awaited movement on the UK REACH Alternative Transitional Registration model following DEFRA's consultation response, but cautioned that cost burdens likely running into hundreds of millions of pounds
    Manufacturing

    Labtex - Fresh thinking and innovative solutions

    Labtex states: "We are proud to provide unique solutions for laboratories and pilot plants across the UK"
    Regulatory

    Lonza Nominates Stephen Fry as Independent Board Member

    Basel, Switzerland, 31 March 2026 – The Lonza Board of Directors today announced the nomination of Stephen Fry as an Independent Member of the Board. Subject to his election at the Lonza Group Annual General Meeting (AGM) in May 2026, Stephen will also be appointed a member of the People and Governance Committee and the Audit and Compliance Committeex
    Research & Development

    Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform

    Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
    Subscribe now